17 results about "Hypoglycemic Effects" patented technology

This invention belongs to the technical field of pharmaceuticals, health foods, and medicines, specifically relating to Russula polysaccharide, its extraction method, and its application in anti-inflammatory, antioxidant, and / or hypoglycemic effects. This invention employs an ultrasound-assisted enzymatic hydrolysis method to extract Russula polysaccharide, thereby significantly improving extraction efficiency, reducing enzyme dosage, protecting the polysaccharide structure, and increasing yield and purity. Furthermore, experimental verification shows that it possesses good anti-inflammatory, antioxidant, and / or hypoglycemic effects, and when combined with Phyllanthus emblica polysaccharide, it synergistically enhances hypoglycemic performance, thus demonstrating significant practical application value.

Provided herein are pharmaceutical formulations comprising glucokinase activator, or a prodrug, or a pharmaceutically acceptable salt, an isotope labeled analogue, a crystalline form, a hydrate, a solvate, or a diastereomeric or enantiomeric form thereof and the use thereof for treating diseases; the pharmaceutical formulations are in the form of immediate-release formulations, extended-release formulations, or combination of immediate-release formulation and extended-release formulations. The pharmaceutical formulations achieved once-a-day therapy for some diseases, in particular, type II Diabetes Mellitus with obesity. The pharmaceutical formulations exhibit sustained 24 hours of glucose-lowering effects. The pharmaceutical formulations also achieved lower Cmax, extended T1 / 2 as well as maintained similar bioavailability and increased MRT compared with commercial Dorzagliatin tablet, enhanced the pharmacology effect of restoring the glucose stimulated GLP-1 secretion in diabetes with obesity.

This invention discloses a meglumine-luteolin complex, its preparation method, and its applications, belonging to the interdisciplinary field of microbiome and drug delivery. Using luteolin as the main material, this invention employs a dual inclusion technique with hydroxypropyl-β-cyclodextrin and meglumine to synergistically prepare a meglumine-luteolin complex with colon-targeted delivery capabilities. This invention significantly improves the delivery efficiency and drug loading of luteolin in the colon through the dual inclusion technique. The preparation process is simple, and it exhibits excellent hypoglycemic effects and colon-targeted release characteristics in the treatment of diabetes and its complications.

The application discloses a quinoa hexapeptide with a blood sugar lowering effect and application thereof, and belongs to the technical field of bioactive peptides. The amino acid sequence of the quinoa hexapeptide PGSPGR is Pro-Gly-Ser-Pro-Gly-Arg. The quinoa hexapeptide PGSPGR has alpha-glucosidase inhibitory activity and can effectively reduce blood sugar level, and therefore, can be applied to preparation of medicines or food for lowering blood sugar. The application further provides a polypeptide containing the peptide segment PGSPGR and a quinoa peptide rich in the polypeptide, and the polypeptide and the quinoa peptide are applied to preparation of medicines or food for lowering blood sugar, thereby providing a new scheme and theoretical basis for treatment of diabetes, and having good market prospect and application potential.

This invention provides a fermented extract of Rehmannia glutinosa, a composition thereof, its preparation method, and its application, belonging to the field of biomedical technology. This invention obtains fermented extracts of black tea and Rehmannia glutinosa by fermenting black tea and Rehmannia glutinosa with a single strain of *Aspergillus cristatus*. Experiments have verified that both extracts, used alone, have good inhibitory effects on dipeptidyl peptidase-4. Further, combining the two extracts and verifying through animal experiments, shows that they have good inhibitory activity against dipeptidyl peptidase-4 in the intestine and feces, while also exhibiting a hypoglycemic effect.

This invention provides a hypoglycemic subspecies of Bifidobacterium animalis (Liver) and its applications. The Bifidobacterium animalis (Liver) subspecies is named Tianshan-1 and is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 35821 on September 5, 2025. Cell experiments show that Tianshan-1 significantly promotes the secretion of GLP-1 from human colorectal adenocarcinoma cells NCI-H716 and upregulates GCG gene expression levels. Animal experiments confirm that this strain significantly increases serum GLP-1 concentration in diabetic mice and reduces fasting blood glucose and glycated hemoglobin levels, with no significant difference in hypoglycemic effect compared to the positive control. This strain is a food-grade safe probiotic with a clear mechanism of action and stable effects, providing a safe, long-lasting, and industrially viable new probiotic resource for diabetes prevention and treatment, with broad application prospects.

This invention provides *Pediococcus lactis* SHI03 and its application in alleviating insulin resistance and type 2 diabetes, belonging to the field of microbial technology. This invention provides *Pediococcus lactis* SHI03, with accession number CCTCC No: M 20242686, and confirms that this strain possesses in vitro α-glucosidase inhibitory activity, exhibiting excellent probiotic and hypoglycemic effects. This invention further provides microbial products containing *Pediococcus lactis* SHI03, including *Pediococcus lactis* SHI03 fermentation broth, *Pediococcus lactis* SHI03 fermentation supernatant, and *Pediococcus lactis* SHI03 cells, and their applications in alleviating high-fat diet-induced insulin resistance and reducing fasting blood glucose in type 2 diabetic mice.

This invention relates to the field of biomedical technology, and more particularly to a *Lactobacillus paracasei* strain with significant hypoglycemic effects. This invention develops an engineered bacterium that continuously secretes a mutant GLP-1 protein, capable of expressing a fusion peptide containing a signal peptide, an enhancing peptide, and the mutant GLP-1 protein. It exhibits good passage stability and can exert a dual therapeutic effect on type 2 diabetes through continuous secretion of the mutant GLP-1 protein and regulation of the gut microbiota. The engineered bacterium of this invention can be used to prepare oral pharmaceutical formulations. Therefore, this invention provides a new technical means for developing non-invasive, cost-effective, and efficient drug delivery strategies targeting GLP-1, and has broad application prospects.

This invention discloses the application of chestnut total burdock ethanol extract in the preparation of hypoglycemic drugs. In this invention, the chestnut total burdock ethanol extract with hypoglycemic effect is obtained by reflux extraction of chestnut total burdock with 70% ethanol. This extract can significantly inhibit the activity of α-glucosidase and has a significant inhibitory effect on postprandial blood glucose levels in T2DM model mice, exhibiting a significant hypoglycemic effect in vivo.

This invention provides a method for preparing a metformin compound hypoglycemic oral solution, relating to the pharmaceutical field, comprising: step S1, pretreatment of traditional Chinese medicine components; step S2, enzymatic hydrolysis of the first group of traditional Chinese medicine components; step S3, supercritical extraction; step S4, preparation of mixed traditional Chinese medicines; step S5, preparation of inclusion complex; step S6, compound formulation; and step S7, post-processing. This method synergistically combines extracts from seven traditional Chinese medicines—bitter melon, phellodendron bark, astragalus root, kudzu root, rehmannia root, ginseng, and privet fruit—with metformin hydrochloride to form a metformin compound hypoglycemic oral solution, balancing the synergy, safety, and stability of traditional Chinese and Western medicines, thereby improving hypoglycemic effects while reducing the incidence of gastrointestinal adverse reactions to metformin.

The application discloses a walnut source DPP-IV inhibiting peptide as well as a preparation, identification and screening method and application thereof, and belongs to the technical field of biological medicines. A series of novel DPP-IV inhibiting peptides, KFPF, IFR, KGFL, KIPF and KLF, are screened and verified from walnut proteins in a high efficiency for the first time. Not only is the rational discovery of high-activity peptides realized through a systematic method of'multi-frequency ultrasonic pretreatment-enzymolysis-ultrafiltration purification-mass spectrometric identification-computer virtual screening-in vitro and in vivo activity verification', but also the clear hypoglycemic effect of the peptides is confirmed in animal experiments. The application provides new candidate molecules for developing natural and safe anti-diabetic functional foods or medicines, and has good industrial value and scientific significance through improving the added value of walnut resources and establishing a replicable active peptide research paradigm.

This invention discloses the application of modified chestnut starch in the preparation of hypoglycemic functional foods and a low-GI modified chestnut starch recombinant rice and its preparation method, relating to the fields of food processing and functional food technology. The modified chestnut starch contains no less than 40% resistant starch; the hypoglycemic functional foods are staple foods, supplementary foods, or dietary supplements for people with type 2 diabetes. The modified chestnut starch exerts a multi-target hypoglycemic effect, not only lowering fasting blood glucose and improving glucose tolerance, but also simultaneously regulating lipid metabolism and reducing liver inflammation and damage. The prepared recombinant rice has a GI value as low as 48.25, while also possessing good edible quality. This solves the technical pain point of existing low-GI recombinant rice, which suffers from "high functionality but low edible quality," achieving a synergistic improvement in hypoglycemic functionality and edible quality. The process is simple, parameters are controllable, and production costs are low, making it suitable for large-scale industrial production and with broad market prospects.

This application relates to the field of hydrogel dressing technology, and particularly to a hydrogel dressing for diabetic foot wounds and its preparation. The hydrogel dressing for diabetic foot wounds provided in this application is obtained by cross-linking and curing a mixture of a hydrogel precursor solution and yeast-loaded hydrogel microspheres; the hydrogel precursor solution is a mixture of carboxymethyl chitosan loaded with spermidine and a first substrate. This application utilizes a hydrogel bilayer encapsulating yeast in both microspheres and hydrogel, inhibiting yeast escape from the hydrogel and avoiding the risk of yeast infection of the wound. Simultaneously, the hydrogel provides a water environment for the biochemical reactions of the yeast, which is beneficial for the yeast to exert its long-term hypoglycemic effect.

This invention relates to the field of mulberry leaf tea hypoglycemic beverage technology, and particularly to a hypoglycemic beverage and a pullulan-modified mulberry leaf tea powder composition. The hypoglycemic beverage is obtained by brewing the pullulan-modified mulberry leaf tea powder composition with boiling water. The beverage is used to lower fasting blood glucose, improve glucose tolerance, and alleviate weight loss. The preparation method of the pullulan-modified mulberry leaf tea powder composition includes: raw material pretreatment, steaming and fixing, low-temperature drying, compound grinding, and grading and screening to obtain the pullulan-modified mulberry leaf tea powder composition. Its hypoglycemic effects are significant and comprehensive: it can effectively lower fasting blood glucose, improve glucose tolerance, and alleviate weight loss symptoms, significantly better than unmodified mulberry leaf tea powder. Furthermore, its preparation process is standardized and easily scalable.

This invention discloses a high-fiber puffed grain powder and its preparation method, belonging to the field of food processing technology. By weight, it comprises the following raw materials: 25-35 parts whole barley flour, 20-30 parts whole oat flour, 15-25 parts whole buckwheat flour, 10-20 parts soybean residue powder, and 5-15 parts wheat bran powder. The whole buckwheat flour contains ≥0.8 mg / g of D-chiral inositol. This invention utilizes the aforementioned high-fiber puffed grain powder and its preparation method, employing a triple synergistic technology scheme of heat-resistant phytase and cellulase combined enzymatic hydrolysis, dry powder moisture adjustment, and low-temperature puffing. This achieves a significant increase in soluble dietary fiber content and a significant optimization of the SDF / IDF ratio, effectively improving mineral bioavailability. Furthermore, low-temperature puffing protects buckwheat flavonoids and D-chiral inositol, inhibits acrylamide formation, ensures product safety, and exhibits multi-target synergistic hypoglycemic effects.

The application discloses a quinoa heptapeptide with a blood sugar lowering effect and application thereof, and belongs to the technical field of bioactive peptides. The amino acid sequence of the quinoa heptapeptide PSDGPGT is Pro-Ser-Asp-Gly-Pro-Gly-Thr. It is verified through animal model experiments that the quinoa heptapeptide can effectively reduce blood sugar level and improve related metabolic indexes. The application further provides a quinoa peptide rich in the peptide segment PSDGPGT. It is verified through animal model experiments that the quinoa peptide has a significant effect on blood sugar reduction, and provides a safe and effective alternative solution for the development of diabetes treatment drugs, and has good market prospects and application potential.

This invention provides a method for preparing vegetable enzymes using probiotic fermentation, belonging to the field of fermentation technology engineering. Using alpine vegetables white radish and purple cabbage as experimental raw materials, this invention employs a compound fermentation of vegetable juice with *Lactobacillus plantarum* and *Lactobacillus paracasei*, using lactic acid content as the fermentation process indicator. First, the use of a radish-and-cabbage compound vegetable juice for fermentation was determined. Further preliminary investigations were conducted on the in vitro hypoglycemic effect and antioxidant activity of the enzyme samples. After lactic acid bacteria fermentation, the nutritional value of the alpine vegetable enzymes is enriched, and their in vitro antioxidant and hypoglycemic abilities are enhanced to a certain extent.